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Drug delivery schedules are key factors in the efficacy of cancer therapies, and mathematical
modeling of population dynamics and treatment responses can be applied to identify better drug
administration regimes as well as provide mechanistic insights. To capitalize on the promise of
this approach, the cancer field must meet the challenges of moving this type of work into clinics.Cancer research and oncology has entered a new era of targeted
therapy (Sawyers, 2004) and patient-tailored therapeutic inter-
vention (Shrager and Tenenbaum, 2014), but resistance (Gottes-
man et al., 2002; Holohan et al., 2013) and tumor heterogeneity
(Anderson et al., 2011; Burrell et al., 2013; Ding et al., 2012;
Gerlinger et al., 2012; Landau et al., 2013) have been a barrier
for realizing the clinical impact of these discoveries. This barrier
is, in essence, a quantitative population genetics problem—the
need to quantitatively describe heterogeneous tumor cell popu-
lations and their dynamics over time and during treatment. Using
such mathematical descriptions, it is then possible to evaluate
which drugs, combinations, and schedules are best for a given
patient. For instance, if drugs are administered at sufficiently
low doses, no drug holidays are necessary to limit the side ef-
fects and reduce patient toxicity; however, if drugs are adminis-
tered at more concentrated doses, which may lead to higher cell
kill, then rest periods are needed to limit side effects. Such drug
holidays can lead to an exponential rebound of the tumor cell
population and hence pose a significant risk for the emergence
of resistance. It is unclear, a priori, which of these two example
strategies are going to be more effective in reducing tumor
burden and preventing the emergence or outgrowth of a resis-
tant tumor subclone. In order to answer this question, several
clinical studies have been performed to identify optimum dosing
frequencies (Hryniuk, 2001; Lake andHudis, 2004). However, it is
both unethical and too time consuming to test all possible dosing
schedules in pre-clinical or clinical studies, and therefore only
limited clinical experimentation can be performed.
Mathematical modeling of the treatment response of hetero-
geneous cell populations represents an attractive avenue toward
narrowing the set of possibilities that should be tested in pre-
clinical models and in the clinical setting (Figure 1). Mathematical
modeling can, in principle, be used to systematically search
through the millions of possible dose administration strategies
(each determined by a unique dose-time profile) and combina-
tion schedules (each determined by a combination of different
drugs administered at different dose-time profiles) to identify
the schedules that maximally extend patient survival. Indeed, asignificant amount of research effort has been devoted to devel-
oping mathematical models that identify the most effective
chemotherapeutic administration regimens using optimization
and control techniques (Coldman and Murray, 2000; Costa
et al., 1992, 1995; Katouli and Komarova, 2011; Kimmel and
Swierniak, 2006; Ledzewicz and Schattler, 2009; Martin et al.,
1992; Martin and Teo, 1993; Murray and Coldman, 2003). These
models are in general aimed at rapidly minimizing the total tumor
burden. However, long-term patient survival depends not only
on quickly decimating the total number of tumor cells, but also
on controlling drug-resistant subpopulations within the tumor.
The simultaneous achievement of these two goals is compli-
cated by the fact that they are often accomplished by exerting
opposing evolutionary selection pressures. Furthermore, both
long-term toxicity and dose-limiting side effects must be
avoided.
Below, we will highlight several examples of promising,
modeling-based findings, some of which represent the few
that have been or will soon be tested clinically. We will then
discuss the challenges that the field must meet to enable more
extensive clinical testing ofmathematically discovered treatment
modalities. In a landmark study, Norton and Simon (Norton and
Simon, 1977) observed that clinical experience was at odds
with a fundamental concept that had been instrumental in
designing dose schedules for the treatment of human cancer:
that small tumors were more sensitive to cytotoxic therapy
than larger tumors of the same histology. The underlying
assumption was that smaller tumors have a large fraction of
actively dividing cells. However, Norton and Simon observed
that, in many cases, the low-dose low-concentration schedules
used for smaller tumors were inferior to more high-concentra-
tion, dose-dense protocols that were a relatively novel approach
at that time. To understand this observation, they probed the
relationship between tumor size and sensitivity to therapy
by inspecting growth curves of tumors exposed to anti-cancer
agents. They found that most untreated malignancies can be
described using a Gompertzian growth law, which predicts an
S-shaped growth curve. According to this law, the growth rateCell 163, November 19, 2015 ª2015 Elsevier Inc. 1059
Figure 1. Exploring Complex Dependencies in Cancer Biology with
Mathematical Modeling
The complexity of cancer includes not only the heterogeneous cell population
of a tumor, but also its interaction with the microenvironment and immune
system and responses to different kinds of treatments.Mathematical modeling
of the impact of these factors on tumor cell population dynamics facilitates the
generation testable hypotheses regarding the evolution of resistance and
identifying prospectively optimum treatment strategies designed to maximize
the chance of a cure.of tumor cells is smallest for both very small and very large tu-
mors but is maximum at the inflection point. Their resultingmath-
ematical model led to the conclusion that a dose schedule
capable of dramatically depleting a tumor of intermediate size
may not be sufficient to cure a small tumor. They thus suggested
more intense schedules, higher doses, and prolonged therapy.
The authors later set out to validate their predictions in a large
randomized clinical trial (Citron et al., 2003) of axillary node-pos-
itive breast cancer. They found, as predicted, that dose-dense
schedules significantly increased disease-free survival and over-
all survival. Their approach thus became the first mathematical
model providing clinically validated predictions.
The model by Norton and Simon was based on the observa-
tion that treatment efficacy can drop if insufficient drug is admin-
istered at a time when the tumor is kinetically less sensitive to
treatment. This ‘‘kinetic resistance’’ is unlike acquired resistance
due to genetic and/or epigenetic events that prevent the drug
from entering the cell, binding to its target, or other mechanisms.
This ‘‘biochemical’’ type of resistance was first mathematically
addressed by Goldie and Colman, who developed a mathemat-
ical model relating the probability of drug sensitivity of a tumor to
the rate at which cells accumulate changes that enable them to
become resistant to therapy (Goldie and Coldman, 1979). The
model assumed that there is a certain probability per cancer
cell division that a resistance-causing (epi)genetic change
arises. By calculating the probability of resistance and the1060 Cell 163, November 19, 2015 ª2015 Elsevier Inc.expected number of resistant cells, the authors found not only
that an increase in the mutation rate increases the probability
of a resistant phenotype emerging, but also that the probability
of there being at least one resistant cell will increase dramatically
during a very short interval in the biological history of the tumor.
The clinical recommendation based on these results was that
therapy be initiated as quickly as possible to maximize the prob-
ability of a cure. This approach was later also predicted to maxi-
mize patient survival due to the emergence of more lethal cancer
states such as metastases (Haeno et al., 2012).
A subsequent extension of this mathematical model consid-
ered two types of resistant cells, each insensitive to a different
chemotherapeutic agent (Goldie et al., 1982). The goal of the
model was to take both types of resistance into account and
identify treatment schedules that would maximize the chance
of a cure by preventing the emergence of doubly resistant cells.
Using a computer program to simulate the development of such
doubly resistant cells, the authors predicted that alternating the
treatment regimen of the two drugs at every cycle would be the
most effective strategy to prevent resistance. This prediction
became known as the Goldie-Coldman hypothesis. A clinical
trial in Italy tested this hypothesis in women with resectable
mammary carcinoma andmore than three positive axillary lymph
nodes (Bonadonna et al., 1995). The patients were randomized
into two treatment arms, either receiving treatments sequentially
or in an alternating fashion. The primary endpoints were relapse
free, and overall survival and the median duration of follow-up
was 9 years. The trial results demonstrated significantly longer
survival, both progression free and overall, for patients who
received the sequential regimen as compared to the alternating
regimen. A subsequent phase II study also evaluated the efficacy
of alternating and sequential regimens of docetaxel and doxoru-
bicin as first-line chemotherapy for metastatic breast cancer
(Paridaens et al., 2003). The alternating and sequential groups
achieved similar objective tumor response rates and median
duration of response, but medial survival times were significantly
shorter in the alternating than the sequential group. Furthermore,
patients receiving sequential therapy were more likely to com-
plete the planned eight chemotherapy cycles and had a lower
incidence of side effects.
These trial results suggest that, at least in those clinical set-
tings, the Goldie-Coldman hypothesis did not hold. However,
the possibility remains that the hypothesis might lead to better
survival times in other cancer types and/or treatment approaches
(such as chemotherapy and radiation therapy). Indeed, several
studies have investigated the outcome of radiation therapy
followed by chemotherapy versus chemotherapy concomitant
with radiation therapy. For example, in non-metastatic breast
cancer, both radiation and chemotherapy are often used as adju-
vant treatment following surgery. A randomized study performed
in the 1990s comparing the sequencing options (of radiation
versus chemotherapy first) showed a reduction in the rate of
distant metastases in the group that received chemotherapy first
(Recht et al., 1996). However, those results were later updated
(Bellon et al., 2005) and shown to be non-significant and were
then disputed in a meta-analysis of three well-documented ran-
domized trials designed to study this question (Hickey et al.,
2013). Thus, the findings regarding implementations of the
Goldman-Coldie hypothesis in the clinic remain mixed, and no
clear validation of the hypothesis has been obtained so far. In
fact, other recent approaches have suggested that it would be
beneficial to administer combination treatment upfront to prevent
the outgrowth of resistance (Bhang et al., 2015; Bozic et al., 2013;
Glickman and Sawyers, 2012).
To determine whether modeling approaches could be applied
to specific resistancemechanisms to individual drugs, we devel-
oped a mathematical model of non-small cell lung cancer cell
response to treatment with the epidermal growth factor receptor
(EGFR) inhibitor erlotinib (Chmielecki et al., 2011) in which resis-
tance was considered to arise predominantly due to a second-
site EGFR mutation (Pao et al., 2005), T790M, which emerges
with a low probability during each sensitive cell division. The
model, similar to the approach by Goldie and Coldman, was
based on a stochastic branching process in which erlotinib-sen-
sitive cells proliferate and die according to rates determined in a
patient-derived cell line. Resistant cells then also proliferate and
die according to rates determined in cells isogenic to the sensi-
tive line apart from the T790Mmutation. These in vitro cell culture
experiments demonstrated that resistant cells had a fitness
lower than sensitive cells in the absence of treatment, a finding
explaining the low frequencies of pre-existing T790M-positive
clones in patients (Chmielecki et al., 2011). The mathematical
model was then used to search through the space of all clinically
tolerated erlotinib schedules to identify the one that would signif-
icantly delay the emergence of T970M-driven resistance. Unlike
the FDA-approved schedule of 150 mg per day, the optimum
consisted of administering a low dose of 50 mg per day together
with twice weekly high-dose pulses at the clinically determined
maximally tolerated dose; the clinical study testing this hypothe-
sis was initiated at Memorial Sloan-Kettering in 2013 (http://
clinicaltrials.gov/show/NCT01967095). Preliminary results show
that this schedule is well tolerated and might reduce the rate of
progression in patients with brain metastases (H.A. Yu et al.,
2015, ASCO, poster).
Although only these three population-based modeling ap-
proaches have so far led to clinical implementation, several other
frameworks have been developed that might soon be tested
in the clinic. These include a mathematical model suggesting
the use of an adaptive therapeutic approach that changes in
response to the variability in both space and time of the tumor
microenvironment, cell phenotype, and response to treatment
(Gatenby et al., 2009) and a model investigating alternative radi-
ation schedules in primary glioblastoma (Leder et al., 2014).
Another recent approach incorporates genetic heterogeneity in
the context of selecting optimum combination strategies (Zhao
et al., 2014). Other groups have used evolutionary game theory
to investigate optimal combination therapies (Basanta et al.,
2012) or have used patient-derived data on tumor stem cell turn-
over to identify prognostic factors (Stiehl et al., 2015).
These studies serve as examples of quantitative descriptions
of heterogeneous cell populations responding to treatment.
The potential of this approach is obvious—it enables us to sys-
tematically investigate hypotheses and test alternative options
for treatment. While mathematical models and pre-clinical
studies of optimized treatment schedules are encouraging, limi-
tations of the approach are also plentiful, as illustrated by thelack of resolution regarding the efficacy of alternating versus
sequential treatments discussed above. The predictive utility of
a model parameterized using a particular pre-clinical model de-
pends on the accuracy not only of the mathematical model, but
also the in vitro or in vivo model vis a vis the human cancer that it
models, as well as the biological assumptions and quality of the
data. The ability of the modeling predictions to be verified or
falsified—not just in a model system, but eventually in a clinical
study—is the essential test. In addition, knowledge is evolving:
more complex aspects of tumor biology are emerging and
need to be incorporated into quantitative modeling approaches.
These include single-cell genetic and epigenetic heterogeneity
(Van Loo and Voet, 2014) and interactions between cancer cells
and the immune system (Sharma et al., 2011) as well as the
microenvironment. The analysis of datasets that comprehen-
sively and quantitatively capture such features may require
novel mathematical approaches and simulation tools that, for
instance, can take advantage of today’s most powerful super-
computers.
Importantly, translation of these concepts and ideal models
into a clinical setting presents both logistical and patient-specific
challenges related to the tumor micro-environment. It is always
difficult to translate a result from a cell line or animal model
into a human clinical study; while there are logistical concerns
related to administering any type of cancer-related treatment,
we will discuss the complexities of treating brain tumor pa-
tients with radiation as a specific example. The first challenge
regarding scheduling altered or ‘‘optimized’’ scheduled radia-
tion, for instance, as proposed in Leder et al. (2014), reflects
the process of treating patients at a specific time each day. There
are staffing concerns with respect to hours of operation and
coordination of scheduling multiple patients throughout the
day on each linear accelerator. There is also the potential of
treatment- or tumor-related toxicity that may fluctuate daily
and may affect whether or not patients can tolerate treatment
at very specific time(s) each day. Most patients are also fatigued
andmay have neurologic symptoms related to their brain tumors
or treatment, which makes it difficult to adhere to a complicated
or specific timing schedule. With careful patient selection and
consideration of scheduling constraints, though, these chal-
lenges may be overcome. The observation of variable tumor vol-
ume among patients reflects the fact that there is great variability
among patients with the extent of their brain tumor resection
related to the location of their tumors in different regions of the
brain and the original extent of the tumor. A patient who has a
gross total resection with only microscopic residual disease
may have a very different response to an altered or optimized
treatment schedule than a patient who has a large, relatively
intact tumor. The potential variability of tumor volume between
brain tumor patients is much greater than in the breast cancer
studies referred to above. This variability could certainly affect
the outcome of an optimized radiation schedule clinical trial.
Other challenges are related to variability in the tumor micro-
environment that may be the result of molecular differences
among patients’ tumors or even more simply the wide range of
medications, or chemotherapy, that brain tumor patients often
require as part of the management of their brain tumors. These
medications may alter the cancer cells’ sensitivity to radiationCell 163, November 19, 2015 ª2015 Elsevier Inc. 1061
or may change the vascular environment and thus indirectly
affect sensitivity to radiation. Even if a study were designed
that controlled for the use of common medications for brain
tumor patients, such as corticosteroids, antiepileptics, or temo-
zolomide, the requirements of some medications are likely to
change during the course of radiation, or patients may discon-
tinue some medications in the midst of their course of radiation
due to toxicity. There are innumerable possibilities of drug
combinations during radiation therapy for brain tumors that
could both positively and negatively impact the effect of radia-
tion. The exact schedule of those standard adjuvant chemo-
therapies, or perhaps investigational immunotherapies, may
also alter the radiosensitivity, or clonal expansion, possibilities
at any given moment. A fully optimized model would need to
incorporate those possible influences as well.
Despite these challenges in designing and effectively executing
a clinical trial to test treatment regimes derived frommathematical
modeling and preclinical data, the endeavor should be pursued.
The results with the current standard treatment are suboptimal,
with a median survival of only 15 months for patients with primary
glioblastoma, the most common type of malignant brain tumor.
However, following surgery, radiation remains the most effective
therapy for glioblastoma, and thus optimizing the effect of radia-
tion remains an attractive option. Historically there have been
many studies of various schedules of radiation for glioblastomas,
includingdoseescalation,but the results fromall aredisappointing
to date (Brada et al., 1999; Horiot et al., 1988; W.J. Curran et al.,
1996, Proc. Am. Soc. Clin. Oncology, abstract). Notably, none of
these studies have been based upon a mathematically optimized
schedule. A hypothesis worth testing is that a clinical trial of a
mathematically optimized radiation schedule could yield an
improved result and could identify altered radiation scheduling
as an opportunity for improved outcomes in other types of brain
tumors or other cancer types.
Despite the logistical, tumor-, and patient-specific challenges
listed above, a trial of an optimized radiation schedule is an
achievable goal with careful patient selection, patient man-
agement, and support from all of the stakeholders, including
clinicians, scientists, and the patients and their families. The glio-
blastomamousemodel study comparing a standard schedule to
an optimized schedule (Leder et al., 2014) proves the concept
that an altered radiation schedule can affect survival. This theory
must be tested in humans with glioblastoma, as these patients
need every opportunity possible to improve their outcome.
Despite the operational, biological, and mathematical obsta-
cles that need to be overcome for successful implementation of
a mathematically predicted treatment strategy in the clinic, we
strongly believe that surmounting these challenges is worth the
effort. The Norton-Simon hypothesis was the first demonstration
that a mathematically derived schedule might be clinically supe-
rior, but many recent and forthcoming approaches hold great
promise, andwehave high expectations that rational quantitative
investigations might contribute to new hope for cancer patients.REFERENCES
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